

CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027

December 21, 2020

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549

Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-251530

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the "Company"), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00 P.M. (Eastern Time) on December 22, 2020, or as soon thereafter as possible on such date.

Very truly yours,

CNS Pharmaceuticals, Inc.

By: /s/ Christopher Downs
Name: Christopher Downs
Title: Chief Financial Officer